サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1379213

生物製剤CDMOの世界市場：2023-2033年

Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033
出版日: | 発行: BIS Research | ページ情報: 英文 165 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
生物製剤CDMOの世界市場：2023-2033年
出版日: 2023年11月11日
発行: BIS Research
ページ情報: 英文 165 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の生物製剤CDMOの市場は、イノベーションと需要の波に乗って急成長すると予測されています。

世界の生物製剤CDMOの市場は、製薬・バイオテクノロジー産業において、生物製剤の開発・製造・試験に特化したサービスを提供する重要な役割を担っています。生物製剤は、タンパク質、抗体、核酸など、生物に由来する複雑な分子であり、癌、自己免疫疾患、感染症などさまざまな疾患の治療において重要性を増しています。

当レポートでは、世界の生物製剤CDMOの市場を調査し、市場概要、市場成長への各種影響因子の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業の分析などをまとめています。

市場区分：

セグメンテーション1：細胞タイプ別

  • 哺乳類
  • 非哺乳類

セグメンテーション2：製品タイプ別

  • 生物製剤
    • モノクローナル抗体
    • 組み換えタンパク質
    • アンチセンス・分子薬
    • ワクチン
    • その他
  • バイオシミラー

セグメンテーション3：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

目次

第1章 市場：業界の展望

  • 動向：現在および将来の影響評価
    • 新たな遺伝子治療と細胞治療
    • 使い捨てバイオプロセス機器
    • 個別化医療への傾向
  • サプライチェーンの概要
    • バリューチェーン分析
    • マーケットマップ
    • 製造コストの予測：CDMO/gm
  • 特許分析
  • 規制状況
  • 製造能力
  • CDMOにアウトソーシングする際に考慮される要素
  • 主な世界的出来事の影響分析：COVID-19・ロシア/ウクライナ・中東危機
  • 市場力学の概要
    • 市場促進要因
    • 市場抑制要因
    • 市場機会

第2章 用途

  • 用途の分類
  • 用途の概要
  • 世界の生物製剤CDMO市場（細胞タイプ別）
    • 哺乳類
    • 非哺乳類

第3章 製品

  • 製品の分類
  • 製品概要
  • 世界の生物製剤CDMO市場（製品タイプ別）
    • 生物製剤
    • バイオシミラー

第4章 地域

  • 地域概要
  • 促進要因・抑制要因
  • 北米
    • 主要参入企業
    • 事業促進要因
    • 事業上の課題
    • 用途
    • 製品
    • 北米（国別）
  • 欧州
    • 主要参入企業
    • 事業促進要因
    • 事業上の課題
    • 用途
    • 製品
    • 欧州（国別）
  • アジア太平洋地域
    • 主要参入企業
    • 事業促進要因
    • 事業上の課題
    • 用途
    • 製品
    • アジア太平洋（国別）
  • ラテンアメリカ
    • 主要参入企業
    • 事業促進要因
    • 事業上の課題
    • 用途
    • 製品
    • ラテンアメリカ（国別）
  • 中東・アフリカ
    • 主要参入企業
    • 事業促進要因
    • 事業上の課題
    • 用途
    • 製品
    • 中東・アフリカ（国別）

第5章 市場：競合情勢・企業プロファイル

  • 競合情勢
  • 企業プロファイル
    • Boehringer Ingelheim Group
    • Lonza Group
    • Samsung Biologics
    • NOVARTIS AG
    • Toyobo Co. Limited
    • Parexel International Corporation
    • Catalent Inc.
    • Binex Co. Limited
    • AGC Biologics
    • AbbVie Contract Manufacturing
目次
Product Code: BHL1501SA

“Global Biologics CDMO Market Set to Surge, Riding the Wave of Innovation and Demand.”

Biologics CDMO Industry Overview

Introduction to Biologics CDMO Market

The global biologics CDMO market plays a crucial role in the pharmaceutical and biotechnology industries, offering specialized services for the development, manufacturing, and testing of biologic drugs. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and nucleic acids, and they have become increasingly important in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

CDMOs in the biologics sector provide a range of services, including cell line development, process development, scale-up, manufacturing, quality control, and regulatory support. These organizations serve as strategic partners for pharmaceutical and biotech companies, allowing them to outsource certain aspects of the drug development and manufacturing process, thereby gaining efficiency, expertise, and flexibility.

Market Segmentation:

Segmentation 1: by Cell Type

  • Mammalian
  • Non-mammalian

Segmentation 2: by Product Type

  • Biologics
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Antisense and Molecular Therapy
    • Vaccines
    • Other Biologics
  • Biosimilars

Segmentation 3: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • MEA

The report provides data for each of these regions, with in-depth country-level analyses, all covering the period from 2022 to 2033.

SegmentationHow can this report add value to an organization?

Product/Innovation Strategy: The global biologics CDMO market has been extensively segmented based on various categories, such as cell type and product type. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: The global biologics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture.

Competitive Strategy: Key players in the global biologics CDMO market analyzed and profiled in the study involve established and emerging players. Moreover, a detailed competitive benchmarking of the players operating in the global biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

SegmentationSome of the prominent names established in this market are:

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing

Table of Contents

1. Markets: Industry Outlook

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Emerging Gene and Cell Therapies
    • 1.1.2. Single-use Bioprocessing Equipment
    • 1.1.3. Trend Toward Personalized Medicine
  • 1.2. Supply Chain Overview
    • 1.2.1. Value chain Analysis
    • 1.2.2. Market Map
    • 1.2.3. Cost of Manufacturing in CDMO/gm Forecast
  • 1.3. Patent Analysis
    • 1.3.1. Awaited Technological Developments
    • 1.3.2. Patent Filing Trend by Country, by Year
    • 1.3.3. Patent Filing Trend by Country, by Country
  • 1.4. Regulatory Landscape
  • 1.5. Prodution Capacity
  • 1.6. Factors Considered While Outsourcing To CDMO
  • 1.7. Impact analysis for key global events- covid19, Russia/Ukraine or Middle East crisis
  • 1.8. Market Dynamics Overview
    • 1.8.1. Market Drivers
    • 1.8.2. Market Restraints
    • 1.8.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Biologiv CDMO Market (by Cell Type)
    • 2.3.1. Mammalian
    • 2.3.2. Non-mammalian

3. Product

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Biologics CDMO Market (by Product Type)
    • 3.3.1. Biologics
      • 3.3.1.1. Monoclonal Antibodies
      • 3.3.1.2. Recombinant Proteins
      • 3.3.1.3. Antisense and Molecular Therapy
      • 3.3.1.4. Vaccines
      • 3.3.1.5. Other Biologics
    • 3.3.2. Biosimilars

4. Region

  • 4.1. Regional Summary
    • Table: Biologics CDMO Market, By Region, ($ Million), 2022-2033
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • Key Market Participants in North America
    • Business Drivers
    • Business Challenges
    • 4.3.1. Application
      • Table: North America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.3.2. Product
      • Table: North America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.3.3. North America (by Country)
      • 4.3.3.1. U.S.
        • Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.3.3.2. Canada
        • Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.4. Europe
    • Key Market Participants in Europe
    • Business Drivers
    • Business Challenges
    • 4.4.1. Application
      • Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.4.2. Product
      • Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.4.3. Europe (by Country)
      • 4.4.3.1. U.K.
        • Table: U.K.Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.K. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.2. Germany
        • Table: Germany Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Germany Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.3. Italy
        • Table: Italy Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Italy Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.4. France
        • Table: France Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: France Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.5. Spain
        • Table: Spain Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Spain Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.4.3.6. Rest of Europe
        • Table: Rest of Europe Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.5. Asia Pacific
    • Key Market Participants in Asia Pacific
    • Business Drivers
    • Business Challenges
    • 4.5.1. Application
      • Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.5.2. Product
      • Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.5.3. Asia Pacific (by Country)
      • 4.5.3.1. China
        • Table: China Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: China Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.2. Japan
        • Table: Japan Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Japan Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.3. India
        • Table: India Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: India Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.4. Australia
        • Table: Australia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Australia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.5.3.5. Rest of APAC
        • Table: Rest of APAC Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of APAC Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.6. Latin America
    • Key Market Participants in Latin America
    • Business Drivers
    • Business Challenges
    • 4.6.1. Application
      • Table: Latin America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.6.2. Product
      • Table: Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.6.3. Latin America (by Country)
      • 4.6.3.1. Brazil
        • Table: Brazil Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Brazil Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.6.3.2. Mexico
        • Table: Mexico Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Mexico Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.6.3.3. Rest of Latin America
        • Table: Rest of Latin America Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
  • 4.7. MEA
    • Key Market Participants in MEA
    • Business Drivers
    • Business Challenges
    • 4.7.1. Application
      • Table: MEA Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
    • 4.7.2. Product
      • Table: MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
    • 4.7.3. MEA (by Country)
      • 4.7.3.1. Saudi Arabia
        • Table: Saudi Arabia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Saudi Arabia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.7.3.2. U.A.E.
        • Table: U.A.E. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: U.A.E. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
      • 4.7.3.3. Rest of MEA
        • Table: Rest of MEA Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
        • Table: Rest of MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033

5. Markets - Competitive Landscape & Company Profiles

  • 5.1. Competitive Landscape
  • 5.2. Company Profile
    • 5.2.1. Boehringer Ingelheim Group
      • 5.2.1.1. Company Overview
        • 5.2.1.1.1. Role of Boehringer Ingelheim Group in Biologics CDMO Market
        • 5.2.1.1.2. Product Portfolio
      • 5.2.1.2. Business Strategies
      • 5.2.1.3. Corporate Strategies
      • 5.2.1.4. Analyst View
    • 5.2.2. Lonza Group
      • 5.2.2.1. Company Overview
        • 5.2.2.1.1. Role of Lonza Group in Biologics CDMO Market
        • 5.2.2.1.2. Product Portfolio
      • 5.2.2.2. Business Strategies
      • 5.2.2.3. Corporate Strategies
      • 5.2.2.4. Analyst View
    • 5.2.3. Samsung Biologics
      • 5.2.3.1. Company Overview
        • 5.2.3.1.1. Role of Samsung Biologics in Biologics CDMO Market
        • 5.2.3.1.2. Product Portfolio
      • 5.2.3.2. Business Strategies
      • 5.2.3.3. Corporate Strategies
      • 5.2.3.4. Analyst View
    • 5.2.4. NOVARTIS AG
      • 5.2.4.1. Company Overview
        • 5.2.4.1.1. Role of NOVARTIS AG in Biologics CDMO Market
        • 5.2.4.1.2. Product Portfolio
      • 5.2.4.2. Business Strategies
      • 5.2.4.3. Corporate Strategies
      • 5.2.4.4. Analyst View
    • 5.2.5. Toyobo Co. Limited
      • 5.2.5.1. Company Overview
        • 5.2.5.1.1. Role of Toyobo Co. Limited Group in Biologics CDMO Market
        • 5.2.5.1.2. Product Portfolio
      • 5.2.5.2. Business Strategies
      • 5.2.5.3. Corporate Strategies
      • 5.2.5.4. Analyst View
    • 5.2.6. Parexel International Corporation
      • 5.2.6.1. Company Overview
        • 5.2.6.1.1. Role of Parexel International Corporation in Biologics CDMO Market
        • 5.2.6.1.2. Product Portfolio
      • 5.2.6.2. Business Strategies
      • 5.2.6.3. Corporate Strategies
      • 5.2.6.4. Analyst View
    • 5.2.7. Catalent Inc.
      • 5.2.7.1. Company Overview
        • 5.2.7.1.1. Role of Catalent Inc. in Biologics CDMO Market
        • 5.2.7.1.2. Product Portfolio
      • 5.2.7.2. Business Strategies
      • 5.2.7.3. Corporate Strategies
      • 5.2.7.4. Analyst View
    • 5.2.8. Binex Co. Limited
      • 5.2.8.1. Company Overview
        • 5.2.8.1.1. Role of Binex Co. Limited in Biologics CDMO Market
        • 5.2.8.1.2. Product Portfolio
      • 5.2.8.2. Business Strategies
      • 5.2.8.3. Corporate Strategies
      • 5.2.8.4. Analyst View
    • 5.2.9. AGC Biologics
      • 5.2.9.1. Company Overview
        • 5.2.5.1.1. Role of AGC Biologics in Biologics CDMO Market
        • 5.2.5.1.2. Product Portfolio
      • 5.2.9.2. Business Strategies
      • 5.2.9.3. Corporate Strategies
      • 5.2.9.4. Analyst View
    • 5.2.10. AbbVie Contract Manufacturing
      • 5.2.10.1. Company Overview
        • 5.2.10.1.1. Role of AbbVie Contract Manufacturing in Biologics CDMO Market
        • 5.2.10.1.2. Product Portfolio
      • 5.2.10.2. Business Strategies
      • 5.2.10.3. Corporate Strategies
      • 5.2.10.4. Analyst View